LUNG CANCER

Experts in lung oncology review 3 clinical cases and discuss individualized treatment approaches for each patient.

Vivek Subbiah, MD, discusses the implications of the phase 1/2 LIBRETTO-001 study, which evaluated selpercatinib as treatment of patients with RET fusion-positive non–small cell lung cancer.

The FDA has granted approval to a generic form of the chemotherapy agent pemetrexed, which is indicated for intravenous administration in patients with locally advanced or metastatic nonsquamous non–small cell lung cancer that have not progressed following 4 cycles of first-line platinum-based chemotherapy.

The FDA accepted a New Drug Application for tepotinib and granted it priority review for the treatment of adult patients with metastatic non–small cell lung cancer who harbor a mutation that leads to mesenchymal-epithelial transition exon 14 skipping, as detected by an FDA-approved test.

A quality improvement tool called “Improving Care Coordination: A Model for Lung Cancer” released by the Association of Community Cancer Centers is a model framework to be used by cancer care providers to improve care coordination for patients with lung cancer who are covered by Medicaid.

Medstar Georgetown University Hospital’s Dr Stephen Liu shares impressions on the way a 57-year-old man with ALK-positive metastatic non–small cell lung cancer was managed, highlighting the rationale for using a second-generation ALK inhibitor as treatment.

The application of liquid biopsies is becoming more common in the field of non–small cell lung cancer as the utility of liquid biopsies in the detection of key biomarkers continues to be confirmed through clinical trials.